Sanofi-Aventis Voluntarily Pauses Ketek Pediatric Trials Pending FDA Consultation
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision to stop pediatric studies of the antibiotic was not at FDA’s request or due to safety concerns, the company says.
You may also be interested in...
Ketek Risk Cannot Be Distinguished From Class, FDA Says
Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.
Ketek Risk Cannot Be Distinguished From Class, FDA Says
Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.
Sen. Grassley Considering Hearings On Safety Of Sanofi-Aventis’ Ketek
The threat follows a meeting with FDA officials that the Finance Committee Chairman found unsatisfactory due to the absence of a line investigator involved with the agency’s scrutiny of the drug.